| Brittany Ann Sullivan, MD | |
|
6105 1st Financial Dr, Burlington, KY 41005-7892 | |
| (859) 586-8200 | |
| (859) 586-8233 |
| Full Name | Brittany Ann Sullivan |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 12 Years |
| Location | 6105 1st Financial Dr, Burlington, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063859452 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 48347 (Kentucky) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Elizabeth Home Care | Florence, KY | Home health agency |
| St Elizabeth Florence | Florence, KY | Hospital |
| St Elizabeth Edgewood | Edgewood, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Summit Medical Group, Inc | 2163326240 | 693 |
News Archive
The use of terahertz waves for biosensing is currently receiving considerable attention. THz waves are able to detect molecular vibrations and rotations, without using labels that can affect the properties of the substances of interest.
Mazor Robotics Ltd., a developer of innovative surgical robots and complementary products, today announced its Renaissance platform received U.S. FDA marketing clearance, expanding the applications of the Renaissance system to include the precise positioning of surgical instruments and implants during brain surgery.
OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells, or tumor-initiating cells, today highlighted new data for vantictumab, a monoclonal antibody targeting the Wnt pathway, at a poster session at the Annual Meeting of the American Society for Clinical Oncology in Chicago, IL.
Members of the largest growing women's organization, the Red Hat Society, kick off the RHS Go Red for Women Program today by trading in their purple dresses for red. The program, which aims to raise awareness of heart disease, the number one cause of death of women in America, encourages Red Hatters from sea to sea to follow the beat and match their hat to their dress.
Xencor, Inc. and MorphoSys AG announced today that they have initiated Phase 1 testing for XmAb®5574 (MOR208), and the first patient has been dosed. XmAb5574 (MOR208) is a potent monoclonal anti-CD19 antibody to which MorphoSys recently gained worldwide access via an exclusive license and collaboration agreement with Xencor.
› Verified 3 days ago
| Entity Name | Summit Medical Group, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881026169 PECOS PAC ID: 2163326240 Enrollment ID: O20031120000738 |
News Archive
The use of terahertz waves for biosensing is currently receiving considerable attention. THz waves are able to detect molecular vibrations and rotations, without using labels that can affect the properties of the substances of interest.
Mazor Robotics Ltd., a developer of innovative surgical robots and complementary products, today announced its Renaissance platform received U.S. FDA marketing clearance, expanding the applications of the Renaissance system to include the precise positioning of surgical instruments and implants during brain surgery.
OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells, or tumor-initiating cells, today highlighted new data for vantictumab, a monoclonal antibody targeting the Wnt pathway, at a poster session at the Annual Meeting of the American Society for Clinical Oncology in Chicago, IL.
Members of the largest growing women's organization, the Red Hat Society, kick off the RHS Go Red for Women Program today by trading in their purple dresses for red. The program, which aims to raise awareness of heart disease, the number one cause of death of women in America, encourages Red Hatters from sea to sea to follow the beat and match their hat to their dress.
Xencor, Inc. and MorphoSys AG announced today that they have initiated Phase 1 testing for XmAb®5574 (MOR208), and the first patient has been dosed. XmAb5574 (MOR208) is a potent monoclonal anti-CD19 antibody to which MorphoSys recently gained worldwide access via an exclusive license and collaboration agreement with Xencor.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brittany Ann Sullivan, MD Po Box 635283, Cincinnati, OH 45263-5283 Ph: (859) 586-8200 | Brittany Ann Sullivan, MD 6105 1st Financial Dr, Burlington, KY 41005-7892 Ph: (859) 586-8200 |
News Archive
The use of terahertz waves for biosensing is currently receiving considerable attention. THz waves are able to detect molecular vibrations and rotations, without using labels that can affect the properties of the substances of interest.
Mazor Robotics Ltd., a developer of innovative surgical robots and complementary products, today announced its Renaissance platform received U.S. FDA marketing clearance, expanding the applications of the Renaissance system to include the precise positioning of surgical instruments and implants during brain surgery.
OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells, or tumor-initiating cells, today highlighted new data for vantictumab, a monoclonal antibody targeting the Wnt pathway, at a poster session at the Annual Meeting of the American Society for Clinical Oncology in Chicago, IL.
Members of the largest growing women's organization, the Red Hat Society, kick off the RHS Go Red for Women Program today by trading in their purple dresses for red. The program, which aims to raise awareness of heart disease, the number one cause of death of women in America, encourages Red Hatters from sea to sea to follow the beat and match their hat to their dress.
Xencor, Inc. and MorphoSys AG announced today that they have initiated Phase 1 testing for XmAb®5574 (MOR208), and the first patient has been dosed. XmAb5574 (MOR208) is a potent monoclonal anti-CD19 antibody to which MorphoSys recently gained worldwide access via an exclusive license and collaboration agreement with Xencor.
› Verified 3 days ago
Kruti Patel, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6159 1st Financial Dr, Burlington, KY 41005 Phone: 859-586-8200 Fax: 859-586-8233 | |
Mark J Kolar, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6159 1st Financial Dr, Burlington, KY 41005 Phone: 859-586-8200 Fax: 859-586-8233 | |
John D. Ammon, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3901 Petersburg Rd, Burlington, KY 41005 Phone: 859-689-4791 | |
Dr. Timothy J Lichter, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1838 Florence Pike Ste B, Burlington, KY 41005 Phone: 859-334-0217 Fax: 859-534-5888 |